New anti-HIV drugs in development.
D016907:Adverse Drug Reaction Reporting Systems; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D002214:Capsules; D002219:Carbamates; D002626:Chemistry, Pharmaceutical; D016049:Didanosine / Q000008:administration & dosage; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D015507:Drugs, Investigational; D005260:Female; D005663:Furans; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D061466:Lopinavir; D008595:Menorrhagia / Q000209:etiology*; D011744:Pyrimidinones / Q000008:administration & dosage*; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage; D019438:Ritonavir / Q000008:administration & dosage* / Q000009:adverse effects; D013449:Sulfonamides / Q000008:administration & dosage
D019380:Anti-HIV Agents; D002214:Capsules; D002219:Carbamates; D015507:Drugs, Investigational; D005663:Furans; D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D018894:Reverse Transcriptase Inhibitors; D013449:Sulfonamides; D061466:Lopinavir; C095108:amprenavir; D016049:Didanosine; D019438:Ritonavir